Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oliceridine plus remimazolam versus sufentanil plus remimazolam for sedation and analgesia in elective surgery
ChiCTR2600133202Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Jun 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of oliceridine, remimazolam and sufentanil (2 arms), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoints: Laryngeal Mask Placement Criteria Score and Vital signs. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
oliceridineremimazolamsufentanil
Beyond the preview
Go deeper on ChiCTR2600133202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133202.